Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	6.73T
Revenue (ttm)	5.08B
Net Income (ttm)	-87.46B
Shares Out	83.22M
EPS (ttm)	-1,074.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	562,683
Average Volume	980,810
Open	80,700
Previous Close	80,900
Day's Range	79,000 - 83,500
52-Week Range	20,500 - 88,700
Beta	-0.89
RSI	70.89
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.